Significance Statement {#s1}
======================

CSF, local vasculature and non-neurogenic astrocytes are niche compartments that provide a microenvironment for regulating adult mouse neurogenesis. We show that OTX2 homeoprotein secreted by choroid plexus into the CSF is transferred into non-neurogenic astrocytes of the ventricular-subventricular zone and a rostral migratory stream where it regulates extracellular matrix and signaling factors. This non-cell-autonomous activity impacts the number of newborn neurons that integrate the olfactory bulb. Thus, we reveal a multilevel role for OTX2 and reinforce the choroid plexus as a key niche compartment affecting adult neurogenesis.

Introduction {#s2}
============

Neurogenesis in the adult mouse brain provides continuous replacement of interneurons in olfactory bulbs (OBs) and is important for olfaction-based learning ([@B38]). Neural stem cells (NSCs), located in the adult ventricular-subventricular zone (V-SVZ) lining the lateral cerebral ventricles, give rise to progenitor cells (the first transient amplifying cells that generate migrating neuroblasts) that migrate though the rostral migratory stream (RMS) to reach the OB where they differentiate as interneurons and integrate into local circuitry. This process is regulated not only by factors intrinsic to the NSCs and progenitors but also by their microenvironment consisting of factors from local vasculature, neuronal circuits, CSF, and local supporting cells ([@B37]; [@B53]; [@B9]). It has been shown that NSCs contact vascular endothelial cells and project into the ventricular wall where their cilia contact CSF, which participates in regulating proliferation and migration through mechanical influence and CSF-borne factors ([@B51]; [@B42]; [@B52]; [@B47]).

The CSF is produced within brain ventricles by the choroid plexuses (ChPs), which express many secreted factors found to influence neurogenesis, including growth factors, morphogens, and guidance clues ([@B19]; [@B34]; [@B54]). Examples of CSF-borne factors include IGF2 (insulin like growth factor 2), which promotes adult NSC renewal ([@B61]); IGF1 and BMP5 (bone morphogenetic protein 5), which promote NSC colonies ([@B54]); NT-3 (neurotrophin-3), which promotes quiescence ([@B15]); and SLIT2 (slit guidance ligand 2), a chemorepulsive factor that participates in neuroblast migration ([@B45]; [@B51]). Neuroblasts and NSCs also contact local non-neurogenic astrocytes ([@B39]; [@B52]), which secrete factors that help to establish and maintain the microenvironment and can influence neurogenesis (for review, see [@B23]). Such factors include DLK1 (delta-like noncanonical notch ligand 1), which induces NSC self-renewal ([@B20]), and thrombospondin 4 (THBS4), which guides neuroblast migration ([@B26]).

Homeoproteins are key regulators of neurogenesis both during embryogenesis and in the adult ([@B14]; [@B48]). This class of transcription factors has the property to act both cell autonomously and non-cell autonomously after secretion and internalization in target cells. The Otx2 homeoprotein is a regulator of embryonic development and embryonic neurogenesis ([@B60]; [@B28]; [@B2]), but its role in adult neurogenesis has not been investigated. OTX2 is expressed by ChP, secreted in CSF, and transfers in brain parenchyma to regulate cortical plasticity in postnatal mice ([@B55]; [@B36]). We hypothesized that OTX2 in the CSF might also accumulate in adult neurogenic niches and impact neurogenesis. Indeed, we find that V-SVZ neurogenesis is regulated by OTX2 expression and secretion by the ChP, and find that OTX2 transfers into supporting astrocytes to control the expression of extracellular factors that impact neuroblast migration.

Materials and Methods {#s3}
=====================

Animals {#s3A}
-------

S129 mice were purchased from Charles River Laboratories. The *Otx2^lox/lox^* (Otx2-lox) mice (S129 background) were donated by Dr. T. Lamonerie, Institut de Biologie Valrose, Nice, France ([@B22]), and *Otx2^+/GFP^* mice were donated by Dr. A. Simeone, Institute of Genetics and Biophysics, Napoli, Italy ([@B1]). The single-chain antibody (scFv) knock-in mouse model (scFv-Otx2 mice, C57BL/6J background) were previously described ([@B7]). Adult mice (3 months old) of either sex were used in all experiments, with littermates distributed equally between control and treated groups while maintaining sex balance. All animal procedures, including housing, were conducted in accordance with the guidelines of the European Economic Community (2010/63/UE) and the French National Committee (2013/118). This research (project \#00704.02) was approved by Ethics Committee 59 of the French Ministry for Research and Higher Education. Mice were conventionally raised (12 h light/dark cycle) in cages with red tunnels, nesting cotton, and food and water available ad libitum.

Mouse surgery {#s3B}
-------------

For surgical procedures, animals were anesthetized with xylazine (2% Rompun, Bayer; 5 mg/kg) and ketamine (Imalgene 500, Merial; 80 mg/kg). Cre-Tat recombinant protein (8-20 µg/ml in 400 mM NaCl, 15% DMSO) or vehicle was injected as previously described ([@B55]). Ten days after Cre-Tat injection, mice were injected intraperitoneally with 150 mg/kg BrdU (B9285, Sigma-Aldrich; at 10 mg/ml diluted in NaCl 0.9%). For OB integration experiments, mice were injected with BrdU twice daily for 5 d, and then housed for 3 weeks before perfusion with PBS. For proliferation experiments, mice were injected with one pulse of BrdU and then perfused with PBS 2 h later. Brains were cut in half along the anterior--posterior axis: the anterior half was fixed for 48 h at 4°C in 4% formaldehyde-PBS, immersed overnight in 20% sucrose PBS, and processed for cryostat sectioning; the posterior half was used to recover fourth ventricle ChP for quantitative PCR analysis of *Otx2* expression.

Astrocyte cell culture {#s3C}
----------------------

Primary astrocytes were prepared from cortex of newborn mouse \[postnatal day 0 (P0) to P4\] of either sex and cultured in 10 ml of DMEM high glucose, 10% serum, 1× antimitotic/antibiotic ([@B40]). After 7 d, astrocytes were passaged into 6-well plates at 400,000 cells/ml, incubated for 14 d, and then treated with 1% Ara-C (in DMEM high glucose, 1% B27, 1× antimitotic/antibiotic) for 24 h before treatment with 100 ng/ml OTX2 protein. After 24 h, treated astrocytes were processed for quantitative PCR analysis.

Immunohistochemistry and histology {#s3D}
----------------------------------

Frozen brains were sectioned (25 or 40 µm) by cryostat and stored at −20°C. For all staining experiments, slides were thawed for 15 min at room temperature, hydrated in PBS, and incubated for antigen retrieval in a steamer for 15 min with 10 m[m]{.smallcaps} citrate buffer, pH 6. After cooling, sections were washed with PBS and incubated in blocking buffer \[0.5% Triton-X, 10% normal donkey serum (Abcam) in PBS\] for 30 min. Primary antibodies were incubated overnight at room temperature \[1/100 rat anti-BrdU OBT0030, AbD Serotec (RRID:[AB_609568](https://scicrunch.org/resolver/AB_609568)); 1/400 rabbit anti-caspase \#9661, Cell Signaling Technology (RRID:[AB_2341188](https://scicrunch.org/resolver/AB_2341188)); 1/250 rabbit anti-OTX2 ab92326 Abcam (RRID:[AB_10562130](https://scicrunch.org/resolver/AB_10562130)); 1/1000 guinea pig anti-DCX (doublecortin) AB2253, Millipore (RRID:[AB_1586992](https://scicrunch.org/resolver/AB_1586992)); 1/200 mouse anti-GFAP G6171, Sigma-Aldrich (RRID:[AB_1840893](https://scicrunch.org/resolver/AB_1840893)); 1/1000 chicken anti-Vimentin AB5733, Millipore (RRID:[AB_11212377](https://scicrunch.org/resolver/AB_11212377)); 1/1000 chicken anti-GFP ab13970, Abcam (RRID:[AB_300798](https://scicrunch.org/resolver/AB_300798))\]. After PBS washes, secondary antibodies (1/2000 donkey anti-IgG Alexa Fluor, Invitrogen; RRID:[AB_142924](https://scicrunch.org/resolver/AB_142924), RRID:[AB_2535794](https://scicrunch.org/resolver/AB_2535794), RRID:[AB_141637](https://scicrunch.org/resolver/AB_141637), RRID:[AB_141607](https://scicrunch.org/resolver/AB_141607)) were incubated for 2 h at room temperature. For DCX labeling, sections were washed with PBS, incubated for 2 h at room temperature with secondary antibody (1/500 biotinylated goat anti-guinea pig ab6907, Abcam; RRID:[AB_954847](https://scicrunch.org/resolver/AB_954847)), washed again with PBS, and incubated for 2 h with conjugated streptavidin (1/2000 Alexa Fluor Streptavidin, Invitrogen; RRID:[AB_2336066](https://scicrunch.org/resolver/AB_2336066)). Sections were washed in PBS, dried, and mounted in DAPI Fluoromount-G (Southern Biotech). TUNEL was performed with the *in situ* cell death detection kit (11684817910 Roche) according to manufacturer instructions. *In situ* hybridization was performed as previously described ([@B55]).

Imaging and quantification {#s3E}
--------------------------

Imaging was performed with an SP5 inverted confocal microscope (Leica), a Nikon 90i upright wide-field microscope, or a Spinning-disk confocal microscope with constant parameters. For BrdU analysis, one 40 µm coronal section every 200 µm was quantified. BrdU counting in the granule cell layer (GCL) and glomerular layer (GL) from the same mice was performed on six sections per animal from bregma +4.0 to its anterior end using an in-house ImageJ macro that automatically detects cells within an ROI. The cell number was normalized by the ROI area for each image; the mean for each animal was reported. This method was validated in initial experiments where counting by hand in parallel gave similar results. BrdU counting in the V-SVZ was performed by hand on 8 × 40 µm coronal sections every 200 µm per animal, from bregma +1.34 to bregma −0.58mm, which represents the anterior V-SVZ in which proliferation is more sustained ([@B21]). Cell numbers were normalized by ventricular wall length.

Quantitative PCR {#s3F}
----------------

Total RNA from fourth ventricle ChP was extracted with the RNeasy Lipid Tissue Mini Kit (Qiagen) with DNA removal. RNA and protein were extracted for extracellular matrix (ECM) composition analysis using the AllPrep DNA/RNA/Protein Mini Kit (Qiagen). RNA was processed with the QuantiTect Reverse Transcription Kit (Qiagen). cDNA was diluted 1:10 with RNase-free water for quantitative PCR samples, which were analyzed in triplicate with a LightCycler 480 II (Roche) and SYBR Green I Master mix. After *T~m~* profile validation, gene expression was determined by the 2*^−ΔΔCt^* method with hypoxanthine guanine phosphoribosyl transferase as the control gene. For expression analysis, the mean expression of vehicle-injected mice or control-treated cells was used for comparison.

Microdissection {#s3G}
---------------

For biochemical analysis, mice were killed by cervical elongation. Brain was placed in cold PBS, dorsal side facing up, and two equidistant longitudinal incisions in each OB were made to divide them into three parts while keeping them attached to the rest of the brain. The V-SVZ microdissection was performed as previously described ([@B43]). Afterward, the hemispheres were placed once again dorsal side facing up and the two sagittal cuts starting from the OB incisions were pursued along the entire length of the brain. The central piece of tissue was laid on its side, and RMS was excised (see [Fig. 2*D*)](#F2){ref-type="fig"}. All tissue samples were stored at −80°C.

Immunoprecipitation and Western blot {#s3H}
------------------------------------

Microdissections were triturated in 100 µl of lysis buffer \[150 mM NaCl, 1% Triton X-100, 100 m[m]{.smallcaps} Tris, pH 7.4, 10 m[m]{.smallcaps} EDTA, 1× protease/phosphatase inhibitor (Roche)\] per 10 mg of tissue and incubated 10 min on ice. Supernatant was recovered in low-bind tubes after centrifugation for 10 min at 16,000 × *g*. Antibody was added \[2.5 µg of anti-OTX2 (ab21990, Abcam) or anti-IgG (ab27478, Abcam)\] and incubated overnight at 4°C with rotation. Protein A Sepharose beads (GE Healthcare) were washed twice and resuspended 1:1 with lysis buffer. Beads (30 µl) were added to each sample and incubated 3 h at 4°C. Beads were recovered by centrifugation for 1 min at 16,000 × *g* and washed five times with 1 ml of cold wash buffer (Lysis buffer with 500 m[m]{.smallcaps} NaCl). Proteins were eluted from the beads with 30 µl of 2× Laemmli buffer, heated for 5 min at 95°C, and stored at −20°C.

Samples were separated on NuPage 4--12% Bis-Tris precast gels (Invitrogen) with 1× MES buffer and antioxidant (Invitrogen) then processed for Western blotting for OTX2 detection. Membranes were blocked in 5% nonfat milk, TBS, 0.2% Tween, incubated with anti-OTX2 (in-house mouse monoclonal) overnight at 4°C then incubated with HRP-conjugated anti-mouse (GeneTex) for 2 h at room temperature. A chemiluminescence reaction was performed with ECL Femto (Thermo Fisher Scientific). These immunoprecipitation experiments were performed three times, with similar results each time.

Statistical analysis {#s3I}
--------------------

Prism 8 software (GraphPad Software) was used for all statistical analyses. Sample size was determined after preliminary experiments. Quantification was normalized by the mean value of vehicle-injected mice samples. Normal data distribution was assessed by the D'Agostino and Pearson omnibus normality test. If a normal test was not passed, the Mann--Whitney test was applied; otherwise, an unpaired *t* test with Welch's correction was used (note *t* test in figure legends). See figure legends for relevant statistical tests, and see [Table 1](#T1){ref-type="table"} for results.

###### 

Statistical analyses

                                          *t*           df               *p*                Mean of vehicle   Mean of Cre-TAT
  --------------------------------------- ------------- ---------------- ------------------ ----------------- -----------------
  Welch's two-sample *t* tests                                                                                
  [Fig. 1*F*](#F1){ref-type="fig"}, GCL   3.590         24.96            0.0014\*\*         214.70            146.90
  Female                                  2.510         9.97             0.0310\*           197.40            137.80
  Male                                    2.684         12.95            0.0188\*           229.5             153.7
  [Fig. 1*F*](#F1){ref-type="fig"}, GL    1.541         24.95            0.1358             63.900            50.090
  GCL+GL area                             1.100         18.63            0.2851             2.756             2.932
  [Fig. 1*H*](#F1){ref-type="fig"}        0.768         12.57            0.4567             32.390            29.200
  Female                                  0.3007        6.670            0.7728             32.39             30.58
  Male                                    0.7001        4.389            0.5192             32.39             27.82
  [Fig. 1*K*](#F1){ref-type="fig"}        0.028         11.79            0.9782             49.890            49.760
  [Fig. 1*N*](#F1){ref-type="fig"}        2.300         10.03            0.0442\*           1706.0            1182.0
  [Fig. 4*E*](#F4){ref-type="fig"}, GCL   3.761         15.72            0.0018\*\*         180.70            120.40
  Female                                  1.593         4.88             0.1734             183.1             130.5
  Male                                    2.593         9.188            0.0286\*           178.7             124.9
  [Fig. 4*E*](#F4){ref-type="fig"}, GL    1.688         11.96            0.1172             49.570            39.320
                                                                                                              
                                          *n* of Veh    *n* of Cre-Tat   *p*                Mean of vehicle   Mean of Cre-TAT
  Mann--Whitney tests                                                                                         
  [Fig. 1*C*](#F1){ref-type="fig"}        21            25               \<0.0001\*\*\*\*   102.6             40.40
  [Fig. 4*C*](#F4){ref-type="fig"}        84            103              0.3283             44.77             41.25
  [Fig. 4*F*](#F4){ref-type="fig"}, GCL   5             5                0.3095             1.524             2.388
  [Fig. 4*F*](#F4){ref-type="fig"}, GL    5             5                \>0.9999           0.933             1.187
  [Fig. 5*A*](#F5){ref-type="fig"}                                                                            
  Efna1                                   5             7                0.0177\*           101.50            153.00
  Efna2                                   5             7                0.2677             100.20            117.40
  Epha4                                   5             7                0.8763             100.30            103.10
  Robo2                                   5             7                0.2020             100.90            90.33
  Thbs1                                   5             7                0.0480\*           108.30            164.70
  Thbs4                                   7             7                0.0012\*\*         102.10            179.90
  Tnc                                     7             7                0.0239\*           99.02             139.80
                                                                                                              
                                          *n* of Ctrl   *n* of OTX2      *p*                Mean of Control   Mean of OTX2
  [Fig. 5*B*](#F5){ref-type="fig"}                                                                            
  Efna1                                   11            8                0.0003\*\*\*       102.500           58.680
  Efna2                                   11            8                0.0001\*\*\*       103.300           52.690
  Epha4                                   11            8                0.0025\*\*         102.600           72.510
  Robo2                                   11            8                0.17740            103.700           81.590
  Thbs1                                   11            8                0.0001\*\*\*       104.600           50.430
  Tnc                                     12            12               0.0015\*\*         105.800           73.870

\**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001.

Results {#s4}
=======

Otx2 knockdown in choroid plexus reduces newborn neurons in the olfactory bulb {#s4A}
------------------------------------------------------------------------------

Intracerebroventricular injections of vectorized Cre recombinase (Cre-Tat) leads to specific recombination of *Otx2* in lateral ventricle ChP of Otx2-lox mice ([@B55]). With this paradigm, we find that Cre-Tat intracerebroventricular injection leads to a strong decrease in OTX2 protein in lateral ventricle ChP compared with vehicle-injected mice ([Fig. 1*A*](#F1){ref-type="fig"}) and also a decrease in *Otx2* mRNA expression in both lateral and fourth ventricle ChP ([Fig. 1*B*](#F1){ref-type="fig"}). While the decrease is not necessarily proportional between both ChPs for a given mouse, when a decrease of \>30% was observed in one ChP, a decrease of at least 30% was observed in the other ChP ([Fig. 1*B*](#F1){ref-type="fig"}). Therefore, the fourth ventricle ChP quantitative PCR analysis is a valid method to assess *Otx2* expression levels in lateral ChP so that anterior tissues can be used for histologic quantification. Otx2-lox mice with \<30% *Otx2* expression knockdown in the fourth ventricle after Cre-Tat intracerebroventricular injection where excluded from subsequent analysis. For the experiments described below, Cre-Tat injections in lateral cerebral ventricles lead to ∼60% decrease in *Otx2* mRNA expression on average in the fourth ventricle ChP ([Fig. 1*C*](#F1){ref-type="fig"}).

![OTX2 knockdown in the choroid plexus reduces newborn neurons in the olfactory bulb. ***A--C***, Conditional *Otx2* knockdown with *Otx2^lox/lox^* mice. ***A***, Staining for OTX2 in lateral ventricle choroid plexus 35 d after intracerebroventricular injection of vehicle or Cre-Tat. ***B***, Comparison of *Otx2* expression levels between fourth and lateral ventricles from the same brain (linked data points represent individual mouse) after vehicle or Cre-Tat intracerebroventricular injection. Dotted line represents 30% decrease in *Otx2* expression. ***C***, Quantitative PCR analysis of *Otx2* expression in fourth ventricle (\*\*\*\**p* \< 0.0001, Mann--Whitney test, 5 experiments). ***D***, Schematic of adult (3 months old) neurogenesis study paradigm. ***E***, Staining for BrdU in a coronal section of olfactory bulb 3 weeks after BrdU injections. ***F***, Quantification of BrdU-positive cells in GCL and GL of the olfactory bulb (\*\**p* \< 0.01, ns *= p* \> 0.05, *t* test, 3 experiments). ***G***, Staining for caspase and DCX in a sagittal section of the RMS. Arrows indicate caspase-labeled neuroblasts throughout the entire RMS. ***H***, Quantification of caspase/DCX colabeled cells in RMS (ns *= p* \> 0.05, *t* test, 3 experiments). ***I***, Schematic of adult V-SVZ proliferation study paradigm. ***J***, Staining for BrdU in a coronal section of the V-SVZ 2 h after BrdU injection. ***K***, Quantification of BrdU-positive cells in V-SVZ (ns *= p* \> 0.05, *t* test, 2 experiments). ***L***, Schematic of adult migration study paradigm. ***M***, Staining for BrdU and DCX in a coronal section of the RMS. ***N***, Quantification of BrdU/DCX colabeled cells in RMS (\**p* \< 0.05, *t* test, 2 experiments). IP, Intraperitoneal; icv, intracerebroventricular; inj, injection; veh, vehicle. Error bars represent SD.](enu0021929270001){#F1}

To assess whether *Otx2* knockdown in ChP alters V-SVZ neurogenesis, we used BrdU treatments to measure either newborn neuron integration in OB (3 weeks postinjection; [Fig. 1*D--F*](#F1){ref-type="fig"}) or cell proliferation in V-SVZ (2 h postinjection; [Fig. 1*I--K*](#F1){ref-type="fig"}) after Cre-Tat or vehicle intracerebroventricular injections. We found a significant decrease in the density of GCL newborn neurons but no change in the density of GL newborn neurons after *Otx2* knockdown ([Fig. 1*F*](#F1){ref-type="fig"}). This change in density was not due to gross structural changes as no significant change in OB area was observed ([Table 1](#T1){ref-type="table"}, GCL+GL area) and was not dependent on sex ([Table 1](#T1){ref-type="table"}). Analysis of caspase-expressing cells revealed no change in cell death in the RMS of Cre-Tat-injected mice ([Fig. 1*G*,*H*](#F1){ref-type="fig"}), suggesting that OTX2 does not affect neuroblast survival. However, *Otx2* knockdown in ChP does not alter V-SVZ cell proliferation ([Fig. 1*K*](#F1){ref-type="fig"}), suggesting that the observed decrease in newborn neurons is due to effects on neuroblast migration. To test this hypothesis, we used a migration paradigm in which we evaluated the density of BrdU/DCX colabeled cells in the RMS 6 d after final BrdU injection ([Fig. 1*L--N*](#F1){ref-type="fig"}). We observed a significant decrease in Cre-Tat-injected animals, suggesting that fewer neuroblasts are leaving the V-SVZ and/or that they are migrating slower ([Fig. 1*N*](#F1){ref-type="fig"}).

Non-cell-autonomous Otx2 in V-SVZ and RMS {#s4B}
-----------------------------------------

Given that OTX2 is secreted from ChP into the CSF and accumulates in brain parenchyma ([@B55]), we hypothesized that OTX2 transfers from ChP to the V-SVZ niche. The *Otx2* locus is silent in V-SVZ and RMS, as shown by the absence of GFP expression in *Otx2^+/GFP^* mice ([Fig. 2*A*,*B*](#F2){ref-type="fig"}) and by *Otx2 in situ* hybridization ([Fig. 2*C*](#F2){ref-type="fig"}). However, OTX2 protein is immunoprecipitated from lysates of V-SVZ and RMS microdissections ([Fig. 2*D*](#F2){ref-type="fig"}) but not from striatum lysates (microdissection beneath V-SVZ); lysates of superior colliculus, in which *Otx2* locus is active, were used as positive controls ([Fig. 2*E*](#F2){ref-type="fig"}). Immunostaining showed the selective presence of OTX2 in a subset of cells within the V-SVZ and RMS ([Fig. 3](#F3){ref-type="fig"}), suggesting that it could be targeting either neural stem cells or progenitor cells directly and/or other cells within the niche. OTX2 is not internalized in neuroblasts (DCX^+^ cells) in V-SVZ but accumulates in a small number of GFAP-labeled cells and many ependymal cells ([Fig. 3*A*,*B*](#F3){ref-type="fig"}). In and around the RMS, OTX2 is again absent in neuroblasts yet is in many GFAP-labeled cells ([Fig. 3*C*,*D*](#F3){ref-type="fig"}).

![OTX2 in RMS and V-SVZ is non-cell-autonomous. ***A--C***, Absence of *Otx2* expression in V-SVZ (***A***, ***C***) and RMS (***B***), as shown by GFP staining in coronal sections of *Otx2^+/GFP^* mice (***A***, ***B***) and by *in situ* hybridization for *Otx2* mRNA in coronal sections of wild-type mice (***C***). Note the expression of GFP in choroid plexus (***A***) and of *Otx2* in septum (***C***). ***D***, Representative sagittal section of RMS microdissection. ***E***, Western blot (WB) analysis of OTX2 immunoprecipitation from lysates of various brain regions (ctrl, IgG control). Bands include OTX2 (\<40 kDa), IgG (25 and 55 kDa), and unknown (∼45 kDa). SC, Superior colliculus; Str, striatum; M.W., molecular weight.](enu0021929270002){#F2}

![OTX2 transfers into supporting cells of neurogenic niches. ***A***, In dorsal V-SVZ, OTX2 staining is detected in some GFAP-labeled astrocytes but not in DCX-labeled neuroblasts. Arrowheads highlight astrocytes containing OTX2. ***B***, Along the lateral ventricular wall, OTX2 staining is detected in vimentin (VIM)-labeled ependymal cells. ***C***, In the RMS, OTX2 staining is detected in GFAP-labeled astrocytes but not in DCX-labeled neuroblasts. Arrowheads highlight astrocytes containing OTX2. ***D***, Orthogonal projection shows OTX2 in the nucleus of astrocytes within the RMS.](enu0021929270003){#F3}

OTX2 protein in regions of neuroblast proliferation and migration suggests that reduced newborn neurons in OB after *Otx2* ChP knockdown in Otx2-lox mice ([Fig. 1*F*](#F1){ref-type="fig"}) could be due in part to OTX2 non-cell-autonomous activity. To test this hypothesis, we used the scFv-Otx2 mouse model, which conditionally expresses a single-chain antibody (scFv) that blocks transfer by sequestering OTX2 in the CSF ([@B7]). Cre-Tat intracerebroventricular injection leads to local scFv-Otx2 expression by ChP cells (GFP reporter; [Fig. 4*A*](#F4){ref-type="fig"}) and secretion into the CSF, which can lead to ∼20% decrease in cortical OTX2 levels after 2 weeks ([@B7]). Here, 35 d after Cre-Tat intracerebroventricular injection, this sequestering of Otx2 in CSF led to ∼10% decrease in OTX2 levels within V-SVZ ([Fig. 4*B*,*C*](#F4){ref-type="fig"}), although it was not statistically significant given the large distribution of OTX2 mean intensity per cell ([Fig. 4*C*](#F4){ref-type="fig"}). Subjecting these mice to the BrdU paradigm for OB integration ([Fig. 4*D*](#F4){ref-type="fig"}) revealed a decrease in newborn neurons in the GCL of Cre-Tat-injected animals and no significant change in the GL ([Fig. 4*E*](#F4){ref-type="fig"}). TUNEL assay revealed no change in neuroblast survival on arrival in the OB ([Fig. 4*F*](#F4){ref-type="fig"}). Together, these results are similar to what was observed in Otx2-lox mice ([Fig. 1*F*,*H*](#F1){ref-type="fig"}) and suggest that the transfer of OTX2 from CSF to V-SVZ plays a significant role in regulating adult neurogenesis. The accumulation of OTX2 protein in supporting cells ([Fig. 3](#F3){ref-type="fig"}) within the niche further suggests that OTX2 regulates V-SVZ neurogenesis through modification of the niche microenvironment.

![Non-cell-autonomous OTX2 is sufficient to regulate adult neurogenesis. ***A***, Efficient recombination in choroid plexus of scFv-Otx2 mice after intracerebroventricular injection of Cre-Tat assessed by GFP reporter. ***B***, Change in OTX2 staining within V-SVZ 35 d after Cre-Tat intracerebroventricular injection. ***C***, Quantification of OTX2 mean intensity per cell in V-SVZ (ns = *p* \> 0.05, Mann--Whitney test). ***D***, Schematic of adult (3 months old) neurogenesis study paradigm with scFv-Otx2 mice. ***E***, Quantification of BrdU-positive cells in olfactory bulb GCL and GL (ns = *p* \> 0.05, \*\**p* \< 0.01, *t* test, 3 experiments). ***F***, TUNEL analysis of GCL and GL to assess cell death in olfactory bulb of scFv-Otx2 mice (ns = *p* \> 0.05, Mann--Whitney test, 2 experiments). IP, Intraperitoneal; icv, intracerebroventricular; inj, injection; veh, vehicle. Error bars represent the SD.](enu0021929270004){#F4}

OTX2 regulates astrocyte factors {#s4C}
--------------------------------

As we observe OTX2 internalization all along the migrating route of neuroblasts ([Fig. 3](#F3){ref-type="fig"}) and found decreased neuroblast migration ([Fig. 1*N*](#F1){ref-type="fig"}) with no change in cell proliferation ([Fig. 1*K*](#F1){ref-type="fig"}), we focused on a possible role for astrocytes found in both V-SVZ and RMS. Several receptors and factors are expressed in V-SVZ and RMS astrocytes that could potentially alter microenvironment composition and signaling. These include ECM proteins such as thrombospondin (Thbs1 and Thbs4) and tenascin-C (Tnc; [@B30]; [@B26]) and signaling molecules such as Robo and Eph receptors along with Ephrin ligands ([@B31]; [@B41]; [@B19]; [@B23]; [@B58]), which may be under transcriptional control of OTX2 ([@B25]; [@B10]; [@B28]; [@B46]). Expression analysis on V-SVZ microdissection lysates from the scFv-Otx2 non-cell-autonomous OTX2 knock-down model showed that *EphrinA1*, *Thbs1*, *Thbs4*, and *Tnc* were upregulated in V-SVZ ([Fig. 5*A*](#F5){ref-type="fig"}). We also found that both *Thbs4* and *Tnc* were upregulated in V-SVZ of Cre-Tat-injected Otx2-lox mice \[mean ± SD: 304.6 ± 114.5% of vehicle (*p* \< 0.0001) and 201.1 ± 94% of vehicle (*p* = 0.0037), respectively\], reinforcing the similarity between both mouse models.

![OTX2 regulates expression of ECM and signaling proteins. ***A***, Quantitative PCR analysis of V-SVZ gene expression in scFv-Otx2 after intracerebroventricular injection of Cre-Tat or vehicle (ns = *p* \> 0.05, \**p* \< 0.05, \*\**p* \< 0.01, Mann--Whitney test). ***B***, Quantitative PCR analysis of OTX2-treated astrocyte cultures (\*\**p* \< 0.01, \*\*\**p* \< 0.001, Mann--Whitney test). Error bars represent the SD.](enu0021929270005){#F5}

To confirm that supporting astrocytes are directly implicated in these changes in the expression of ECM and signaling factors, we turned to an *in vitro* astrocyte model involving aged astrocytes from newborn mouse cortex to provide mature astrocytes that do not contain NSCs typical of V-SVZ cultures. Indeed, cultured late juvenile and adult cortex astrocytes do not give rise to neurons, while cultured V-SVZ astrocytes retain this potential ([@B35]). However, astrocyte cultures derived from early juvenile mouse cortex show low *Thbs4* expression ([@B5]), and cultured astrocytes typically show enriched expression of *Thbs1* and repression of *Thbs4* compared with their *in vivo* counterparts ([@B12]; [@B18]). While astrocytes in our *in vitro* model do not perfectly represent isolated V-SVZ supporting cells, they are suitable for assessing non-cell-autonomous OTX2 activity on mature and differentiated astrocytes given the absence of confounding NSCs. Consistent with changes observed *in vivo*, treatment with OTX2 protein resulted in the downregulation of *EphrinA1*, *Thbs1*, and *Tnc* ([Fig. 5*B*](#F5){ref-type="fig"}), with the exception of *Thbs4*, which is not expressed in our cultured astrocytes and is in keeping with previous studies. In this *in vitro* paradigm, OTX2 was also found to regulate *EphrinA2* and *Eph4* expression, which further highlights differences with adult V-SVZ astrocytes. Nonetheless, these results are in agreement with OTX2 transfer to niche astrocytes to regulate neurogenesis by controlling ECM composition and signaling.

Discussion {#s5}
==========

OTX2 homeoprotein was previously found to act non-cell-autonomously in cortical interneurons ([@B57]; [@B55]; [@B36]). The *Otx2* locus is not active in the V-SVZ and RMS, but the protein can be immunoprecipitated, indicating that OTX2 homeoprotein transfers not only into several distant cortical regions but also into regions proximal to the lateral ventricles. In the cortex, OTX2 is specifically internalized by parvalbumin interneurons, which have a unique and stable ECM called perineuronal nets (PNNs) that often stain for the lectin *Wisteria floribunda* agglutinin (WFA; [@B57]). The specificity of internalization arises from a glycosaminoglycan-binding motif in OTX2 protein ([@B8]; [@B36]), and although specific target glycosaminoglycans of OTX2 have yet to be identified, OTX2 preferentially binds disulfated chondroitin sulfate proteoglycans ([@B8]; [@B44]; [@B6]). However, staining for WFA is not detected in the V-SVZ (data not shown), which is not surprising given that PNNs are synonymous with consolidation of ECM and a break on plasticity---events that would counter the function of the neurogenic niche. The hypothesis of ECM--OTX2 interaction accounting for the specific internalization remains the most plausible, given that homeoprotein cell-surface receptors have not been found ([@B6]). Thus, the specificity of OTX2 for astrocytes within the V-SVZ and RMS suggests that they are expressing glycosaminoglycans with high affinity for OTX2.

Through specific conditional recombination in the ChP of two mouse models, similar decreases in neurogenesis were observed. In Otx2-lox mice, recombination results in loss of local OTX2 expression in the ChP, while in scFv-Otx2 mice it results in sequestering OTX2 in the CSF due to single-chain antibody secretion by the ChP ([@B7]). The first model includes both potential cell-autonomous effects of loss of OTX2 in the ChP as well as potential non-cell-autonomous effects through reduced levels of secreted OTX2. The second model comprises only non-cell-autonomous effects as only secreted OTX2 is affected. This is confirmed by the absence of autocrine effects (i.e., CSF OTX2 signaling on ChP) assessed by ChP mRNA levels of OTX2 transcription targets on scFv expression ([@B7]). Since both models provide a similar reduction in the number of newborn neurons, it suggests that OTX2 non-cell-autonomous function is of primary importance for adult neurogenesis. Interestingly, we observe an effect despite a nonsignificant reduction in OTX2 accumulation in V-SVZ, which is likely due in part to the large distribution of mean OTX2 staining intensity. Small (∼20%) decreases in OTX2 in adult mouse visual cortex induce cortical plasticity ([@B55]; [@B7]), and OTX2 transcriptional targets can be activated at one concentration of OTX2 yet be suppressed at lower or higher concentrations ([@B3]). Concentration-dependent targets of homeoprotein are shown to be dependent on chromatin state, whereby some targets are concentration insensitive while others are highly concentration sensitive ([@B27]). Indeed, we find significant changes in some but not all putative targets of OTX2 in the V-SVZ despite the potentially subtle changes in OTX2 accumulation.

Previous studies on the role of factors secreted by the ChP mainly show effects on the proliferation of NSCs and transit-amplifying cells, as well as effects on maintaining NSC quiescence and the migration of neuroblasts ([@B9]; [@B54]). These factors were found to signal through quiescent and/or activated NSCs, such as for BMP5, IGF2, or NT-3 ([@B15]; [@B61]; [@B54]), or were found to signal directly through neuroblasts to regulate migration, such as for SLIT1/2 ([@B45]). Interestingly, ROBO2 is expressed by supporting astrocytes within the V-SVZ and RMS and influences the migration of neuroblasts, which express SLIT1 ([@B31]). This suggests that SLIT1/2 from ChP can also be signaling through supporting astrocytes. We find the ChP knockdown of OTX2 reduces GCL newborn neurons without significantly modifying of cell proliferation or cell death but by modifying neuroblast migration into the RMS. However, one might expect reduced neuroblast migration to lead to a proportional reduction in dying neuroblasts. Yet cell death is difficult to study in this population given the spatiotemporal heterogeneity of their death and the high variability in their detection ([@B50]). Thus, we cannot formally exclude that OTX2 is also affecting cell death. Nonetheless, OTX2 protein transfers in GFAP-positive cells in the V-SVZ, in the majority of GFAP-positive cells in the RMS, and in ependymal cells of the V-SVZ; this profile points to modification of the neurogenic niche instead of direct modification of progenitor activity.

Given the precedent of ECM and supporting astrocytes for regulating neuroblast migration ([@B23]; [@B32]), we examined OTX2-dependent expression of local ECM and signaling molecules expressed within V-SVZ and RMS. The RMS is composed of a compacted neuroblast network forming chains that migrate along blood vessels and are surrounded by astrocytic processes ([@B39]; [@B59]). While it is clear that RMS-associated astrocytes interact with neuroblasts ([@B31]), the role of astrocytes for neuroblast migration is not well known. Studies show that neurogenesis is impacted by the composition of ECM in stem cell niches ([@B17]), which include astrocyte-derived TNC and THBS4 in V-SVZ and RMS ([@B30]; [@B5]; [@B26]), and OTX2 has been shown to regulate *Tnc* and *Thbs4* transcription ([@B25]; [@B46]). While *Tnc* knock-out mice show no signs of altered adult neurogenesis ([@B33]), *Thbs4* knock-out adult mice show reduced newborn neurons in the OB, yet no defect of embryonic neurogenesis ([@B26]). Cell-autonomous OTX2 expression was found to parallel *Thbs4* expression in the retina ([@B29]), suggesting that OTX2 activity is context dependent, as previously suggested ([@B11]). However, given the global dysregulation observed, we cannot come to a conclusion on the role of the different ECM molecules and interacting proteins. Nevertheless, changes in V-SVZ expression of *Tnc* and *Thbs4* on *Otx2* knockdown are in keeping with a transcriptional role for non-cell-autonomous OTX2 in astrocytes.

As OTX2 was found in RMS astrocytes and signalization with neuroblasts is still an open question ([@B13]), we tested whether genes coding for migration and signaling factors might be modified in our models. *Robo2* is strongly expressed in RMS astrocytes and is required for proper RMS organization and guidance of neuroblasts ([@B31]), and it has been hypothesized that astrocyte-derived laminin helps to form RMS scaffold for neuroblast migration ([@B4]). Also, *EphA4* and *EphrinA2* are expressed in RMS and V-SVZ, supporting astrocytes (along with other combinations of Ephs and Ephrins), and EPHA4 has been shown to be critical for maintaining a compact and organized RMS ([@B58]). While OTX2 has been shown to bind *Robo2* promoter ([@B28]) and to regulate *Ephrin-A2* ([@B49]), we did not detect any changes in V-SVZ expression after OTX2 knockdown. However, OTX2 affected expression more widely in cultured mature astrocytes, including the expression of *EphA4* and *EphrinA2*, suggesting that it has the potential to influence RMS organization and/or that its activity is differentially regulated among astrocyte subtypes. While these cultured astrocytes are not derived from V-SVZ, they reflect better the activity of OTX2 in supporting astrocytes given that V-SVZ cultures are dominated by GFAP-expressing NSCs. This *in vitro* model confirms that transfer of OTX2 into V-SVZ can regulate the expression of genes found in supporting astrocytes.

Our results add to the growing research on homeoprotein transduction ([@B16]) and add to the complexity of ChP function, which is essential for brain homeostasis and neuroimmune regulation ([@B56]; [@B24]). OTX2 signaling through the CSF to cortical interneurons has been shown to regulate brain plasticity throughout the cortex and impact higher cognitive functions. We must now consider that ChP-derived OTX2 accumulates in diverse regions of the brain and that altering its concentration within CSF can influence a wide range of brain functions. Within the V-SVZ, OTX2 regulates ECM molecules and factors that likely impact neuroblast migration and ultimately newborn neuron numbers. These findings reinforce both ChP and V-SVZ non-neurogenic astrocytes as key niche compartments affecting adult neurogenesis.

Synthesis {#s6}
=========

Reviewing Editor: Margaret McCarthy, Univ of Maryland School of Medicine

Decisions are customarily a result of the Reviewing Editor and the peer reviewers coming together and discussing their recommendations until a consensus is reached. When revisions are invited, a fact-based synthesis statement explaining their decision and outlining what is needed to prepare a revision will be listed below. The following reviewer(s) agreed to reveal their identity: Pelin Cengiz.

This paper titled: "OTX2 signals from the choroid plexus to regulate adult neurogenesis" reports the role of homeoprotein transcription factor OTX2 in migration of the neural stem cells (NSCs) originating from ventricular (choroid plexus) and subventricular zone (V-SVZ) to the olfactory bulb. This study investigates a role for Otx2, a protein made by the choroid plexus and secreted into the CSF, on neurogenesis in the adult olfactory system Authors use different genetically modified mouse models including the Otx2lox/lox, otx2+/GFP, single chain antibody (ScFv) knockin mouse. The main findings of the study are: 1) Knocking down Otx2 in choroid plexus reduces newborn neurons in the olfactory bulb and OTX2 regulates V-SVZ neurogenesis though modification of the niche microenvironment 2) OTX2 secreted by the choroid plexus transferred to supporting cells of the subventricular zone and rostral migratory stream. This is an interesting study and the data presented is important. However, some of these conclusions are not supported by the data in the presence of inadequately presented sample sizes, statistics and sex of the mice. The regulation of adult neurogenesis by CSF factors is very interesting, and the methods for altering Otx2 are creative and well-characterized. However, more information is needed about the methods used for analyses, and the authors should be cautious about interpreting their findings.

Introduction:

1\. The Introduction suggests that CSF factors other than OTX2 have been found to influence neurogenesis, but although these factors are mentioned several times none are named or their specific effects described. This information is directly relevant to the current study, so the Introduction should be expanded to name these factors, or at least those for which evidence is strongest, and specify their specific effects on proliferation, cell survival, etc. The effects of these other factors should also be compared to those of OTX2 in the Discussion.

2\. Primary hypothesis is missing

Methods:

1\. Background and the age of the mouse models are not presented. What is the age of the mice used for these experiments? Were these pups, weanlings, adults? The age should be stated, and if a range of ages was used, the Methods should specify whether age was matched across treatment groups. The methods say that mice "of either sex" were used. Were mice matched for sex across treatment groups? Were males and females compared to look for differences (or confirm an assumed lack of difference) in treatment effects?

2\. Although it is mentioned that both sexes were included, data pertaining to males and females are not presented separately. In addition, the sex of the astrocytes that are cultured are not presented.

3\. Certain methodologies are not referenced such as preparation of the astrocyte culture, or immunostaining with biotinylated secondary antibody immunostaining, and for reproducibility purposes the methods need references.

4\. There is not enough information given regarding the methods for counting BrdU+ cells. These counts form the basis for the major conclusions of the study, so the counting methods are critical. The methods state that sections were counted every 200 um, but was this done throughout the entire olfactory bulb and subventricular zone? If so, this would suggest that counts were done according to stereological methods, which would be ideal. If not, densities should be calculated, but the number of sections analyzed in each brain should be given. In addition, the areas measured should be described, including what each area comprised (the GCL or entire cross-section of the bulb? Did the areas measured differ across groups? If cell division were decreased that could shrink the thickness of the SVZ, resulting in similar cell density but fewer total dividing cells - an argument for using stereological counting methods.

5\. The use of normalization should also be justified. It is difficult to understand why normalization was used, since this must have been across groups, and not to compensate for differing expression in each animal, for example. Actual cell density values should be given unless there is a strong reason for normalizing, because normalization provides less information.

6\. The organization of the Methods section is confusing, with information about surgical anesthesia in the "Animals" section rather than the "Mouse surgery" section, information about fixation and sectioning of brains in "Mouse surgery" rather than "Immunohistology and histology", etc. Some reorganization would be helpful for the reader.

7\. The immunohistochemical methods do not include a DNA denaturing step, which is generally required for BrdU staining. It is difficult, if not impossible, to determine the quality of the BrdU staining from the photos because the magnification is so low. It is clear that there is quite a bit of background staining in the olfactory bulb sections (Fig 1E) but the labeled cells are no apparent. Much higher magnification is needed for photos in Fig 1E,H,K; Fig 3A,C (individual panels on the left); and Fig 3B. The current photos are not large enough to show what they intend to demonstrate.

5\. Details on other staining such as caspase is not presented.

Statistics:

1\. Statistical table that includes the results, name of the test (main effects), etc\...is missing

2\. More detailed description of the sample size calculation and power is needed, especially when some the sample sizes ranges from 8-20+.

Results:

1\. Following brain injury, apoptosis in female brain is caspase dependent. In males it is caspase independent. Checking only the caspase dependent pathway in a cohort of mice that has male predominance will make results and conclusion unreliable. Especially the conclusion of the OTX2 migrates due to lack of caspase mediated cell death may not be correct. The male and female differentiation in apoptosis can be determined by checking the PARP, bax or bcl2 expressions.

2\. The numbers of individual data points seem to vary quite a bit from graph to graph within an experiment (figure). Why were some analyses not done in all animals? Or do individual data points in the graphs represent something other than animals (such as sections)? The TUNEL analysis shown in Figure 4C seems to have been done in a small subset of the animals; this very small N could be preventing detection of a difference in cell death.

3\. Cell death is difficult to study in this population, because cells could be differentially dying at multiple places along the migratory pathway and at many different times. It is also difficult to study using cell death markers because the numbers of cells labeling with these markers at a given time is so small, making variability high and effects difficult to detect. Failing to see a change in dying cells in a given region at a given time point is not strong evidence that there is no effect on cell survival. Counting BrdU+ cells all along the RMS at multiple time points could better address the effects on cell survival. The suggestion that the decrease in newborn neurons is due to effects on migration is therefore premature, but also difficult to understand logically. If cells were failing to migrate properly, that should decrease the numbers of cells dying along the route (labeled with caspase), which was not observed, as well as the numbers of DCX expressing cells in the RMS (not analyzed). The data that the authors have do not seem to favor a migration impairment over a survival impairment.

4\. From the clustering of points in Figure 1C, it appears that the authors have combined points from both treatment groups for their correlation. This is not a valid way to run a correlation, as group effects could make the factors appear correlated, which appears to have happened. The data from the two treatment groups needs to be run separately. It appears that when that is done, neither of the two clusters will show a within-cluster correlation.

5\. Figures lack clarity. Need arrows to show direct the reader where exactly the expressions of certain proteins are increased or decreased. The photos in Figure 3 should have labels to make the orientation and location of the ventricle (in SVZ photos) clear to the reader. These photos clearly show OTX2 protein in vimentin and GFAP expressing cells in the SVZ and RMS. I expected the next figure to show that this staining is missing, or significantly decreased, by scFv-Otx2, but there are no data speaking to this. These data would strengthen the case that Otx2 entering the SVZ/RMS from the CSF is modulating neurogenesis.

6\. What is cf. HPRT, this needs to be written out at least once.

7\. Location of the images that are presented in the figures needs to be written out in detail in figure legends. For example granular cell layer of the olfactory bulb, etc..

8\. What is the reasoning of showing IHC of OTX2 in lateral ventricle and presenting the 4th ventricle choroid plexus (CP) % OTX2 expression and not the lateral ventricle CP % OTX2 expression? What is the significance of the correlation shown in Fig 1 C?

9\. What is the expression of OTX2 in the RMS?

Discussion:

1\. Limitations of the study are not discussed.

2\. How does the cortical astrocytes behave differently than subventricular zone astrocytes? Since the astrocyte culture was obtained from cortical astrocytes, how the results are interpreted is important.

3\. The results of the study need to be discussed in detail to make the importance of the results clearer.

4\. What would be the clinical significance of these results under physiological and pathological conditions?
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